The Research Progress and Challenges of Peptide Drugs in the Treatment of Non-Small Cell Lung Cancer: From Mechanism to Clinical Practice
DOI:
https://doi.org/10.62051/ijphmr.v2n3.03Keywords:
Non-small cell lung cancer (NSCLC), Peptide drugs, Targeted therapy, Immune modulationAbstract
Non-small cell lung cancer (NSCLC) is the most common lung cancer subtype, with rising incidence and poor prognosis due to difficult early diagnosis. Peptide drugs, known for their high selectivity, low toxicity, and flexible structure, are emerging as promising NSCLC treatments. This review covers recent advances in peptide drugs, focusing on mechanisms for targeting pathways, modulating immunity, and overcoming resistance. Challenges such as stability, bioavailability, and delivery efficiency are discussed, alongside strategies like chemical modifications, nanocarriers, and computational design to improve efficacy. Future prospects include combining peptide drugs with current therapies and utilizing AI for precise NSCLC treatment.
References
[1] Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. CA: A Cancer Journal for Clinicians, 70(1), 7-30. https://doi.org/10.3322/caac.21590
[2] Jemal, A., Thun, M. J., Ries, L. A., Howe, H. L., Weir, H. K., Center, M. M., ... & Edwards, B. K. (2004). Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer, 101(1), 3-27. https://doi.org/10.1002/cncr.20288
[3] Subramanian, J., & Govindan, R. (2010). Lung cancer in ‘never-smokers’: A unique entity. Oncology (Williston Park), 24(1), 29-35.
[4] Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553(7689), 446-454. https://doi.org/10.1038/nature25183
[5] Goldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E., ... & The IASLC Lung Cancer Staging Project. (2016). The IASLC lung cancer staging project: Proposals for the revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 11(1), 39-51. https://doi.org/10.1016/j.jtho.2015.09.009
[6] Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: Current status and future directions. Drug Discovery Today, 20(1), 122-128. https://doi.org/10.1016/j.drudis.2014.10.003
[7] Otvos, L., & Wade, J. D. (2014). Current challenges in peptide-based drug discovery. Frontiers in Chemistry, 2, Article 62. https://doi.org/10.3389/fchem.2014.00062
[8] Zhang, T., Wan, B., Zhao, Y., Li, C., Liu, H., Lv, T., ... & Song, Y. (2019). Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment. Translational Lung Cancer Research, 8(3), 302-316. https://doi.org/10.21037/tlcr.2019.04.12
[9] Zhu, Q. G., Zhang, S. M., Ding, X. X., He, B., & Zhang, H. Q. (2017). Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. Oncotarget, 8(34), 57680-57692. https://doi.org/10.18632/oncotarget.17016
[10] Skoulidis, F., & Heymach, J. V. (2019). Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 19(9), 495-509. https://doi.org/10.1038/s41568-019-0179-8
[11] Soda, M., Choi, Y. L., Enomoto, M., Takada, R., Yamashita, Y., Ishikawa, S., ... & Mano, H. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448(7153), 561-566. https://doi.org/10.1038/nature05945
[12] Attili, I., Asnaghi, R., Vacirca, D., Adorisio, R., Rappa, A., Ranghiero, A., ... & Passaro, A. (2024). Co-occurring driver genomic alterations in advanced non-small-cell lung cancer (NSCLC): A retrospective analysis. Journal of Clinical Medicine, 13(15), 4476. https://doi.org/10.3390/jcm13154476
[13] Yang, Y., & Fan, S. (2024). Small cell lung cancer transformations from non-small cell lung cancer: Biological mechanism and clinical relevance. Chinese Medical Journal Pulmonary and Critical Care Medicine, 2(1), 42-47. https://doi.org/10.1016/j.pccm.2023.10.005
[14] Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y. L., ... & Paz-Ares, L. (2017). Lung cancer: Current therapies and new targeted treatments. The Lancet, 389(10066), 299-311. https://doi.org/10.1016/S0140-6736(16)30958-8
[15] Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., & Engelman, J. A. (2013). EGFR mutations and ALK rearrangements in lung cancer: Prognostic and predictive implications. American Journal of Respiratory and Critical Care Medicine, 188(7), 823-829. https://doi.org/10.1164/rccm.201212-2030CI
[16] Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M., Kim, H. R., Ramalingam, S. S., ... & AURA3 Investigators. (2017). Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. New England Journal of Medicine, 376(7), 629-640. https://doi.org/10.1056/NEJMoa1612674
[17] Skoulidis, F., Li, B. T., Dy, G. K., Leal, T. A., Hei, Y. J., & Sotorasib Lung Cancer Group. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. New England Journal of Medicine, 384(25), 2371-2381. https://doi.org/10.1056/NEJMoa2103695
[18] Leonetti, A., Facchinetti, F., Minari, R., Gnetti, L., Aletto, C., Filippi, A. R., & Tiseo, M. (2018). Not all ALK inhibitors are created equal: Novel insights into ALK resistance mechanisms and their clinical impact. Cancer Treatment Reviews, 66, 47-57. https://doi.org/10.1016/j.ctrv.2018.03.002
[19] Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., ... & Pembrolizumab NSCLC Investigators. (2018). Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. New England Journal of Medicine, 379(21), 2040-2051. https://doi.org/10.1056/NEJMoa1810865
[20] Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., ... & Cancer Genome Atlas Research Network. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124-128. https://doi.org/10.1126/science.aaa1348
[21] Rotow, J., & Bivona, T. G. (2017). Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 17(11), 637-658. https://doi.org/10.1038/nrc.2017.84
[22] Saw, P. E., & Song, E. W. (2019). Phage display screening of therapeutic peptides for cancer targeting and therapy. Protein & Cell, 10(11), 787-807. https://doi.org/10.1007/s13238-019-00664-0
[23] Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021). Trends in peptide drug discovery. Nature Reviews Drug Discovery, 20(4), 309-325. https://doi.org/10.1038/s41573-020-00135-8
[24] Zorzi, A., Deyle, K., & Heinis, C. (2017). Cyclic peptide therapeutics: Past, present, and future. Current Opinion in Chemical Biology, 38, 24-29. https://doi.org/10.1016/j.cbpa.2017.02.006
[25] Thundimadathil, J. (2012). Cancer treatment using peptides: Current therapies and future prospects. Journal of Amino Acids, 2012, Article 967347. https://doi.org/10.1155/2012/967347
[26] Borrelli, A., Tornesello, A. L., Tornesello, M. L., & Buonaguro, F. M. (2018). Cell penetrating peptides as molecular carriers for anti-cancer agents. Molecules, 23(2), Article 295. https://doi.org/10.3390/molecules23020295
[27] Zhang, Y., Luo, Y., & Zhang, Z. (2017). Peptide-based multifunctional nanomaterials for tumor imaging and therapy. Advanced Drug Delivery Reviews, 110-111, 13-37. https://doi.org/10.1016/j.addr.2016.08.003
[28] Liu, S., & Kurzrock, R. (2014). Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treatment Reviews, 40(7), 883-891. https://doi.org/10.1016/j.ctrv.2014.04.004
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Journal of Public Health and Medical Research
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
